Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 15/20 | 0.73 |
| ▸ | CYP1A1 | P04798 | 14/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 14/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.59 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.59 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.59 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.59 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.59 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25706432 | 0.84 | CYP1A2 (1.00) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL145083 | 0.84 | CYP1A2 (0.76) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL3172829 | 0.83 | CYP1A2 (0.81) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL12090696 | 0.83 | CYP1A2 (0.81) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL3172823 | 0.83 | CYP1A2 (0.81) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL1547729 | 0.83 | CYP1A1 (0.63) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL9545111 | 0.81 | CYP1A2 (0.70) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL96291 | 0.81 | ALDH1A1 (1.00) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL11108516 | 0.81 | CYP1A2 (0.70) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 | |
| SCHEMBL30411244 | 0.81 | CYP1A2 (0.70) | CYP1A2CYP1A1CYP1B1ALDH1A1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858641-B2 | melanocortin-4 receptor (MC4-R) agonists such as (3R,5S)-N-(2-{2-[2-fluoro-4-(methyloxy)phenyl]ethyl}-1-oxo-1,2-dihydroisoquinolin-6-yl)-3,5-dimethyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide, used for the treatment of obesity or diabetes | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-7858631-B2 | Substituted pyrido [2,3-d] pyrimidinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-12-28 | — | — | US | claimed |
| EP-1551834-B1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-08-25 | — | — | EP | claimed |
| US-7749985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2010-07-06 | — | — | US | claimed |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | claimed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | claimed |
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2009-11-19 | — | — | US | claimed |
| US-7585996-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-08 | — | — | US | claimed |
| EP-1686996-A4 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | claimed |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2008-06-19 | — | — | US | claimed |
| WO-2004112793-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | claimed |
| EP-1478626-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| US-20040019049-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2004-01-29 | — | — | US | claimed |
| WO-2003099818-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | CHIRON CORPORATION (US) | 2003-12-04 | — | — | WO | claimed |
| US-20030195187-A1 | Guanidino compounds | CHIRON CORPORATION | 2003-10-16 | — | — | US | claimed |
| WO-2003066597-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| EP-0767174-A1 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1997-04-09 | — | — | EP | claimed |
| US-5376684-A | Aminobutyric acid antagonist; antiepileptic agent | CIBA-GEIGY CORPORATION (US) | 1994-12-27 | — | — | US | claimed |
| EP-0543780-A2 | Novel aminoalkanephosphinic acids and their salts | CIBA-GEIGY AG (CH) | 1993-05-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, NAPEPLD, AASDHPPT | CYP1A2 1321/4885CYP1A1 2098/4885CYP1B1 1934/4885 |
| US-20030195187-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | CYP1A2 3707/4885CYP1A1 3026/4885CYP1B1 3647/4885 |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, NAPEPLD, AASDHPPT | CYP1A2 1321/4885CYP1A1 2098/4885CYP1B1 1934/4885 |
| US-20040019049-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | CYP1A2 2054/4885CYP1A1 1294/4885CYP1B1 2149/4885 |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | MC4R, MC5R, MC2R | CYP1A2 2110/4885CYP1A1 1701/4885CYP1B1 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.